In 2022, we had a laser-sharp focus on one thing: to enable patients in need to gain access to high-impact medicines in resource-challenged countries. In pursuit of that goal, we forged deep partnerships, provided access to innovative treatments, expanded diagnostic testing, brought data-driven rigor to our internal systems, and launched programs designed to help patients overcome barriers to access.

By the end of 2022 more than 34,000 patients in over 75 of the most resource-constrained countries had received treatment and care, free of cost.

While satisfying and deeply humbling, we know there is much work to be done. Our Equity in Action strategic plan, launched in 2021, provided a clear roadmap to accelerate health equity for patients in need around the world.

This renewed commitment focused us on three priorities that drove our efforts throughout last year, our 25th anniversary year. So, how did we do in 2022?

1. TREAT MORE PATIENTS

We are happy to say we reached an additional 3,000 newly diagnosed patients—that is 3,000 families who can smile a little easier now. Our treatment access programs reached patients in Laos and Guinea for the first time, bringing the number of countries where we support patients to 77, and, importantly, grew our Social Determinants of Health programs by 38%, helping patients overcome barriers to treatment access such as transportation costs. In a world of impersonal online interactions, our teams stayed true to our unwavering patient focus through more than 52,000 unique one-on-one personal interactions with patients and caregivers in 2022.

2. AMPLIFY OUR VOICE

Pat accepted the role of chairing the Access to Oncology Medicines (ATOM) council, a union for the International Cancer Control coalition comprised of deeply committed organizations and individuals intent on accelerating access to cancer treatment. This offers a great opportunity for us to make the patient voices heard by leveraging the combined resources of the council.

3. SUSTAIN OUR WORK

To sustain our momentum, we strengthened our staff in regions and functions where the needs are most critical. Their innate cultural understanding and enthusiasm never fail to amaze. Our continued strength and impact depend on our sustained partnerships. Reflecting this, we launched the Humanitarian Partnership for Access to Critical Treatment (Humanitarian PACT) for Advance Breast Cancer. With breast cancer still the leading cause of death for women worldwide, this is not just an exci first for us, but also an important step forward for women in low-resource settings.

In closing, we have a clear mission, a core set of beliefs to guide our actions, and a measurable plan to take forward. Our patients keep us inspired and motivated. Our supporters, donors, and friends provide the wind to our sails. We have never been more confident in our ability to accelerate health equity in collaboration with our partners for the many thousands in need who are waiting. We share this annual report to update you on our progress and ask for your continued support.

With sincere gratitude and hope for the future,

PAT GARCIA-GONZALEZ
CEO and Co-Founder
PAULA BOULTBEE
Board President

OUR MISSION

Our mission is to accelerate health equity. We do this by delivering medication, technology, and services to patients facing cancer and other critical illnesses, focusing our energy on those whom no one else is helping.

OUR VISION

Our vision is a world where all people can access high-impact medicines, where geography is not destiny, and where everyone can strive for health with dignity and hope.
2022 NUMBERS

380 partner medical institutions

9M+ daily doses of life extending cancer and rare disease medication delivered

73 global team members serving patients

91% of patients supported, continuing from previous years

77 low- and middle-income countries supported

8,890 molecular diagnostic tests administered

327 treatment shipments delivered through our supply chain

52K number of one-to-one contacts by our team with patients

4 GeneXpert diagnostic machines donated

505 partner healthcare professionals

15 countries receiving access to new treatments

3,072 patients reaching treatment for the first time

34,131 total number of patients with cancer and critical diseases receiving access to treatment

29,829 patients treated for Chronic Myeloid Leukemia (CML)

3,124 patients treated for Gastrointestinal Stromal Tumors (GIST)

529 patients treated for Renal Cell Carcinoma (RCC)

375 patients treated for Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (Ph+ ALL)

143 patients treated for Dermatofibrosarcoma Protuberans (DFSP)

71 patients treated for ALK- and ROS1-positive non–small cell Lung Cancer (ALK+ & ROS1+ NSCLC)

40 patients treated for Hypereosinophilic syndrome Chronic Eosinophilic Leukemia (HES/CEL)

9 patients treated for Myelodysplastic Syndromes/Myeloproliferative Disorders (MDS/MPD)

6 patients treated for Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

3 patients treated for Primitive NeuroEctodermal Tumors (pNET)

2 patients treated for Systemic Mastocytosis (SM)

02

03
We expanded our access programs beyond cancer for the first time, piloting a new program for Transthyretin Amyloid Cardiomyopathy (ATTR-CM), an ultra-rare disease.

Supporters across the globe came together to celebrate the 25th anniversary of The Max Foundation raising $264,000 to help accelerate equal access to treatment.

We provided nearly 9,000 diagnostic tests, 48% more than the prior year, recognizing the importance of diagnosis and treatment monitoring.

We grew our support to help patients overcome barriers by 38%, expanding initiatives for transportation to treatment centers, tuition grants to keep children of cancer patients in schools, patient meetings to support and educate, and direct assistance via our helpline.

We launched the Humanitarian PACT for Advanced Breast Cancer to increase global access to treatment, care, and support for women living with advanced breast cancer.

We expanded geographically to provide targeted access where there is none today, opening a treatment access program in Laos and Guinea in December, making significant progress on our core strategic goal.

Dr. Yangchen, Physician from Bhutan, comments that it is not just getting access to innovative medicines she appreciates and admires, but the fact that The Max Foundation works with partner countries to link local doctors to global experts, help improve diagnostic capabilities, and train local teams.

Physician Perspective

Dr. Yangchen from Bhutan

“I’ve seen that Max looks beyond just donations alone. Because a donation, while it is beneficial for a resource-constrained country like Bhutan, we are looking forward to future collaborations in terms of how Max has been helping other countries in terms of training the manpower, giving access to reagents, testing equipment. So, we look forward to a greater and much more fruitful collaboration in the future. Thank you so much for helping people all over the world. It is an inspiring and noble job that you are doing.”
TREAT MORE PATIENTS

PROGRESS ON OUR PRIORITIES

We increased patient access to treatment significantly in 2022 in parts of the world that need them the most. More than 3,000 newly diagnosed patients received treatment at no cost across Africa, the Middle East, Eastern Europe, Central Asia, Latin America, and Southeast Asia. We expanded our presence to include Laos and Guinea for the first time, bringing our geographic network to 77 countries with 380 institutions and 505 physicians collaborating with us to help patients.

Studies suggest that conditions in which people are born, grow, work, live, and age, along with the forces that govern their lives, could be significant influencers on their health outcomes. These factors – termed Social Determinants of Health (SDoH) – can be powerful barriers to treatment. In 2022, patient assistance through our five SDoH programs, designed to help patients overcome these barriers, increased by 38%, reaching more than 3,200 people. Our teams logged more than 52,000 unique one-on-one interactions with patients and caregivers throughout the year. We opened a new SDoH program in three new countries, bringing our SDoH patient reach to 16 countries.

Accurate diagnosis and monitoring remains a significant barrier for patients in low-resource countries. Worldwide, we increased our critical diagnostics support by 48% in tests delivered and by 86% in the use of Spot On CML tests through our collaboration with Radich Lab at Fred Hutch Cancer Center.

PATIENT PERSPECTIVE

“Although some discouraged me from taking on treatment, I am happy that I did and encourage others to take on the treatment and experience first-hand a life-altering journey with the opportunity that The Max Foundation provides.”

Joanne from Papua New Guinea

Joanne and her family. Joanne is now in stable health after being provided with medicines. She says she realizes the “importance of treatment and how it has positively impacted my life.”
AMPLIFY OUR VOICE

PATIENT PERSPECTIVE

“I can't find the appropriate words in vocabulary to express my feelings for Max! Imagine someone helping you from far away and you don't even know his/her name, you don't know who he/she is to thank for, he/she continues to support for years, and you continue your life – this is something incredible.”

Murad from Armenia

Murad (second from left), a father of three daughters, who has been on treatment for leukemia for 19 years says, “I think life is a fairy tale. I believe in wonders and amazements”.

PROGRESS ON OUR PRIORITIES

Externally and internally, we advanced closer to our goal of continuing to amplify our patients’ voices. Externally, Pat assumed chairmanship for Access to Oncology Medicines Coalition (ATOM) Council, a global partnership sponsored by the Union for International Cancer Control, that brings together 40 leading organizations with the single shared goal of improving access to essential cancer medicines in lower-to middle income countries.

Internally, we launched a new communications department headed by a Vice President designed notably to solidify our organizational outreach, strengthen our presence across key channels, and provide a consistent voice to our multiple stakeholders as we move beyond access to medicine to include Health Systems Strengthening and Social Determinants of Health (SDoH) initiatives.
SUSTAIN OUR WORK THROUGH ROBUST PARTNERSHIPS

PROGRESS ON OUR PRIORITIES

Looking ahead to building and sustaining our momentum, we grew the strength of our organization through selective hires in much-needed regions and functions. Our diverse global team are conversant in nearly 40 languages, giving them unique local cultural relevance, strength, and influence to help advance patient needs at the country level.

Reflecting our approach to accelerating health equity through strategic partnerships, we launched Humanitarian Partnership for Access to Critical Treatment (Humanitarian PACT) to provide access to treatment for HR positive/HER2 negative advanced breast cancer patients. Founding partners of the Humanitarian PACT for Advanced Breast Cancer include the ABC Global Alliance, the American Society for Clinical Pathology, Cepheid, and Novartis AG. This innovative collaboration is grounded in a shared commitment to increase global access to treatment for people living with cancer.

PHYSICIAN PERSPECTIVE

“In 1997, I entered the medical faculty of the Azerbaijan Medical University and have participated in writing a guideline for patients with leukemia and currently involved in writing a Guideline on Treatment of Follicular Lymphoma for physicians. I have also run patient education for leukemia patients several times. I want to thank The Max Foundation for giving me the chance to work with innovative medicines, to give incurable patients a chance to survive, to give hope and equity in health.”

Dr. Abbasova, physician from Azerbaijan

“Becoming a doctor is not only about diagnosing correctly or prescribing effective medicine for treatment; it is about healing by understanding, talking, making patients feel strong and recovering”.

- Dr. Oksana Abbasova
REVENUE & EXPENSES FOR THE YEAR ENDING JUNE 30, 2022

REVENUE

<table>
<thead>
<tr>
<th>Description</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>In-kind pharmaceutical contributions*</td>
<td>$ 307,241,383</td>
</tr>
<tr>
<td>Contributions, grants, &amp; sponsorships</td>
<td>$ 11,539,837</td>
</tr>
<tr>
<td>Diagnostic program revenue</td>
<td>$ 317,805</td>
</tr>
<tr>
<td>Other Income</td>
<td>$ 4,252</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>$ 319,103,277</strong></td>
</tr>
</tbody>
</table>

EXPENSES

<table>
<thead>
<tr>
<th>Description</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Program expenses</td>
<td>$ 7,844,916</td>
</tr>
<tr>
<td>Program in-kind expenses</td>
<td>$ 365,352,278</td>
</tr>
<tr>
<td>Management &amp; general expenses</td>
<td>$ 1,861,527</td>
</tr>
<tr>
<td>Fundraising expenses</td>
<td>$ 691,527</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>$ 375,750,248</strong></td>
</tr>
</tbody>
</table>

*The Organization recognizes in-kind contributions consisting of pharmaceuticals, medical devices, and related products. These goods are recorded as inventory and revenue at fair value at the time received and as a reduction to inventory and program expense when the goods are distributed. Pharmaceutical inventory is released using a specific identification method based on expiration date and is reviewed at least annually for impairment. Pharmaceutical inventory is disposed and written off as obsolete when it is determined the pharmaceutical cannot be imported into a specific country of destination with shelf-life sufficient to comply with local importation regulations and the Organization's own guidelines.

DONORS & SUPPORTERS

Your invaluable support allows people facing cancer around the world to live with dignity and hope. Without your generosity and support, we will not achieve our ambitious goals to reach more patients in need. Together, we can overcome inequities in health outcomes and provide the vital medicines to patients no matter where they live. Thank you for joining our mission to accelerate health equity.

HUMANITARIAN PACT PARTNERS

- ABC Global Alliance
- American Society for Clinical Pathology
- Bristol Myers Squibb
- Cepheid
- Inqute Corporation
- Novartis AG
- Pioneer in Treatment Access
- Pfizer Inc.
- Takeda

CORPORATE PARTNERS

- AA Pharmacy
- Armenian Missionary Association of America
- Auburn Rotary Club
- Bank of America
- BD
- Bellevue Breakfast Rotary Club
- Bellevue Rotary Club
- Bourne Capital Partners, LLC
- Bristol Myers Squibb Foundation
- Copiers Northwest
- F5
- Fearay
- Federal Way Rotary Club
- Fred Hutchinson Cancer Center
- GenePath Diagnostics
- GRAIL
- Heavycity Music
- HMME
- Issaquah Rotary Club
- Kent Rotary Club
- Lake Union Rotary Club
- Mercer Island Rotary Club
- Occidental Lodge #72 F. & A.M.
- Redmond Rotary Club
- Roche
- Rotary District 5030
- Seagen
- Shoreline Rotary Club
- Suquamish Tribe
- Tanner Pharma Group

INDIVIDUAL DONORS

- Oluyemi Ajayi
- Paul Aliu
- Benjamin & Tinya Anderson
- Alicia Annamalay
- Julian Atim
- Ellen Baker
- Ciandra Barber
- Liz Barrett
- Jerry P. Scott, CPA & Odette Batik
- Gregory Bell
- Cari & Greg Benn
- Matt & Kim Benson
- David Berg
- Terri-Ann Betancourt
- Dr. Beverly Mitchell
- Josué & Nicole Blanco
- Aaron Blank
- Phil Boeder
- Stephanie Bohannan
- Nicole Bond Edwards
- Francis Bouchard
- Paul & Paula Boulbage
- Edward Briercheck
- Randall Broad
- Carol Choi
- Brent Christofferson
- Laura Cisar
- Viswa Colluru
- Wilma Conenat
- Christopher & Jamie Conner
- Liza & Geoffreys Cook
- Eric & Dipti Cox
- David Craig

INDIVIDUAL DONORS

- Oluyemi Ajayi
- Paul Aliu
- Benjamin & Tinya Anderson
- Alicia Annamalay
- Julian Atim
- Ellen Baker
- Ciandra Barber
- Liz Barrett
- Jerry P. Scott, CPA & Odette Batik
- Gregory Bell
- Cari & Greg Benn
- Matt & Kim Benson
- David Berg
- Terri-Ann Betancourt
- Dr. Beverly Mitchell
- Josué & Nicole Blanco
- Aaron Blank
- Phil Boeder
- Stephanie Bohannan
- Nicole Bond Edwards
- Francis Bouchard
- Paul & Paula Boulbage
- Edward Briercheck
- Randall Broad
- Carol Choi
- Brent Christofferson
- Laura Cisar
- Viswa Colluru
- Wilma Conenat
- Christopher & Jamie Conner
- Liza & Geoffreys Cook
- Eric & Dipti Cox
- David Craig
INDIVIDUAL DONORS CONTINUED

Irina Datikashvili-David
Ted Davis
Sonia de Bary Pereda
Amadou Diarra
Drs. Jerald Radich & Dorcas Dobie
Talia Jaide Ni Dufaigh
Liz Dwyer
Rolando Valencia & Joyce Egonia
Patrick Flanagan
Frank R. Foresta Jr
Pat Garcia-Gonzalez
Cristin Gordon-Maclean
Sarah Casarella & George Gradwohl
Nancy Grande
Raiza Ramirez & Gabriel Guerrero
Sarah Hamilton
William Comenat & Carol Ann Mejdrich
Arda Melkonian
Siew Gim Lee
Daniel Lieberman
Fausto Loberiza
Albert Lui
Lutz Hegemann, MD, PhD
Ashley Kirk
Pinky Herrera & John Hibbard
Nisith Kumar
Lindsay Kurs
Sofia Ibarra
Jian Irish
Mariam Izoria
Lawrence N Shulman, MD & Linda Jacobs PhD, NP
Julie Jenson
Patricia Jewell
Eric Johnson
Elaine Kapjian-Pitt
Karen M. Kaspryzk
Patricia Keegan
John Ketchum
Ken Kieffer
Andrew Kim
Ami King
Kevin King

LEADERSHIP

LEADERSHIP TEAM

Pat Garcia-Gonzalez
Chief Executive Officer
Wilma Comenat
Vice President, Development
Geoff Cook
Vice President, Communications
Inés García González
Region Head for Latin America

BOARD OF DIRECTORS

Paula Boultbee
President of the Board
Pat Garcia-Gonzalez
Chief Executive Officer
Robert Farmer
Honorary Board Member
Susan Jerian, MD
Board Member, President and Founder, ONCORD, Inc.

HEMATOLOGY ADVISORS

Jorge E. Cortes, MD
Brian J. Druker, MD
Andres Hochhaus, MD
Timothy Hughes, MD

ONCOLOGY ADVISORS

Fatima Cardoso, MD
Matias Chacon, MD
George D. Demetri, MD
Alexandru Eniu, MD
Yehoda M. Martel, MD MSCE

CARDIOLOGY ADVISOR

Dr. Juan Pablo Costabel
### AFRICA & MIDDLE EAST
- Faith Afolabi
- Tenaye A. Ashebir
- Perpertual Asiama
- Mario Borain
- Geraldine Botha
- Nicole Jordaan
- Maxane Kilosho
- Mmamolahlegi Mahopo
- Tresor Mbuji
- Lucy Mwangi
- Kayinfa Nicole
- Catherina Scheepers
- Vimbi Taruzedzara
- Kafui Vodounou

### ASIA PACIFIC, EASTERN EUROPE & CENTRAL ASIA
- Nor Aina Abd Rahim
- Mariam Izoria
- Socheatha Jim
- Min Jia Lim
- Nelia Medina
- Nur Fatima Nadia Mohd Nor
- Nur Izzati Mohd Rodzi
- Mei Ching Ong
- Wirat Sae-Kuai
- Sukhrob Saliev
- Aytan Shirinova
- Tang Thi Thanh Thao
- Chani Kan Wongsamai

### LATIN AMERICA
- Victoria Duhalde
- Melisa Gisele Fazio
- Cynthia Figueroa Guerra
- Ines Garcia Gonzalez
- Mariana Rubi Gonzalez
- Lyat Granati
- Martha Rosario Molina
- Jacqueline Montufar
- Cristian Neves
- Maria Julia Sánchez

### HEADQUARTERS
- Mahmoud Albailah
- Craig Anderson
- Alicia Annamalay
- Mercedes Arteaga
- Wilma Comenat
- Geoff Cook
- Diane Cryder
- Patrick Flanagan
- Pat Garcia-Gonzalez
- Tomara Henderson
- Angel Kaushish
- Emma Kgopa-Chabangu
- Mmamolahlegi Mahopo
- Alexander Lay Martinez
- Emily Muirhead
- Bryan Murphy-Eustis
- Pooja Patil
- Patti Pearce
- Raiza Ramirez
- Sam Reddy
- Abigail Russo
- Jennifer Rynning
- Nicholas Schmidt
- Charmaine Vazquez
- Michael Wrigglesworth
- Andrielle Yost

### SOUTH ASIA
- Sweta Agrawal
- Ashok Boricha
- Phillip Fernandes
- Santosh Kadam
- Priyanka Kandalgaokar
- Shrutika Kaspaile
- Prasad Kothekar
- Dipanwita Maiti
- Azim Mohd
- Ashika Naik
- Beena Narayanan
- Urvashi Negi

### JYOTY Parameshwaran
- Sudha Samineni
- Julie Soundarava
- Shalini Subramanian
- Komal Surve
- Anshika Tandon
- Viji Venkatesh
- Anona Walter
<table>
<thead>
<tr>
<th>PARTNER INSTITUTIONS</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ARGENTINA</strong></td>
</tr>
<tr>
<td>Academia Nacional de Medicina</td>
</tr>
<tr>
<td><strong>BRAZIL</strong></td>
</tr>
<tr>
<td>Centro de Hematologia e Hemoterapia – Universidade</td>
</tr>
<tr>
<td><strong>BURKINA FASO</strong></td>
</tr>
<tr>
<td>Centre Hospitalier Universitaire Valago Ouedrago</td>
</tr>
<tr>
<td><strong>CAMBODIA</strong></td>
</tr>
<tr>
<td>Mercy Medical Center Cambodia</td>
</tr>
<tr>
<td><strong>CAMEROON</strong></td>
</tr>
<tr>
<td>Hospital General Yaoundé</td>
</tr>
<tr>
<td><strong>CHILE</strong></td>
</tr>
<tr>
<td>Clínica Iconos</td>
</tr>
<tr>
<td><strong>CHINA</strong></td>
</tr>
<tr>
<td><strong>CUBA</strong></td>
</tr>
<tr>
<td><strong>CZECH REPUBLIC</strong></td>
</tr>
<tr>
<td><strong>DENMARK</strong></td>
</tr>
<tr>
<td><strong>DEMOCRATIC REPUBLIC OF CONGO</strong></td>
</tr>
<tr>
<td><strong>DOMINICAN REPUBLIC</strong></td>
</tr>
<tr>
<td><strong>ECUADOR</strong></td>
</tr>
<tr>
<td>Hospital Metropolitan</td>
</tr>
<tr>
<td>SOLCA Núcleo de Quito</td>
</tr>
<tr>
<td><strong>EL SALVADOR</strong></td>
</tr>
<tr>
<td>Hospital Nacional Rosales</td>
</tr>
<tr>
<td><strong>ESTONIA</strong></td>
</tr>
<tr>
<td>North Estonian Medical Centre</td>
</tr>
<tr>
<td><strong>ETHIOPIA</strong></td>
</tr>
<tr>
<td>Tikur Anbessa (Black Lion) Hospital</td>
</tr>
<tr>
<td><strong>FIJI</strong></td>
</tr>
<tr>
<td>Colonial War Memorial Hospital</td>
</tr>
<tr>
<td><strong>GABON</strong></td>
</tr>
<tr>
<td>Institut de Cancérologie Angondje</td>
</tr>
<tr>
<td><strong>GEORGIA</strong></td>
</tr>
<tr>
<td>M.Zodelava Hematology Clinic</td>
</tr>
<tr>
<td><strong>GHANA</strong></td>
</tr>
<tr>
<td>Komfo Anokye Teaching Hospital</td>
</tr>
<tr>
<td><strong>GUATEMALA</strong></td>
</tr>
<tr>
<td>Hospital General San Juan de Dios</td>
</tr>
<tr>
<td><strong>GUINEA</strong></td>
</tr>
<tr>
<td>CHU Ignace Deen Conaky/Guinee</td>
</tr>
<tr>
<td><strong>HAITI</strong></td>
</tr>
<tr>
<td>Zanmi Lasante</td>
</tr>
<tr>
<td><strong>HONDURAS</strong></td>
</tr>
<tr>
<td>Centro de Cancer Emma R. De Callejas</td>
</tr>
<tr>
<td><strong>INDIA</strong></td>
</tr>
<tr>
<td>A.M.R.I Hospital</td>
</tr>
<tr>
<td>ACHARYA TULSI REGIONAL CANCER TREATMENT AND RESEARCH</td>
</tr>
<tr>
<td>Action Cancer Hospital</td>
</tr>
<tr>
<td>AIMS Bhubaneswar</td>
</tr>
<tr>
<td>Alexis Hospital, All India Institute of medical science</td>
</tr>
<tr>
<td>All India Institute Of Medical Science (AIIMS)</td>
</tr>
<tr>
<td>Amala Hospital</td>
</tr>
<tr>
<td>American Oncology Institute</td>
</tr>
<tr>
<td>Amrita Institute of Medical Sciences</td>
</tr>
<tr>
<td>Ananta Medical College and Research Centre</td>
</tr>
<tr>
<td>Antia's Clinical &amp; Haematology Lab</td>
</tr>
<tr>
<td>Apex Wellness Hospital</td>
</tr>
<tr>
<td><strong>APOLLO CANCER INSTITUTES</strong></td>
</tr>
<tr>
<td>Apollo Cancer Hospital, Navi Mumbai</td>
</tr>
<tr>
<td>Apollo Hospitals, Madurai</td>
</tr>
<tr>
<td>Apollo Multispeciality Hospital</td>
</tr>
<tr>
<td>Apollo Specialty Hospitals (Chennai)</td>
</tr>
<tr>
<td>Aranya Multi-Speciality Clinic Arundodaya Medical Centre</td>
</tr>
<tr>
<td>Asravatham Super Speciality Hospital</td>
</tr>
<tr>
<td>Aster Medcity Hospital</td>
</tr>
<tr>
<td>Aster MIMS Hospital</td>
</tr>
<tr>
<td>Ayush Haematono Clinic B. L. Kapoor Super Speciality Hospital</td>
</tr>
<tr>
<td>Bahra Hospital and Medical Research Center</td>
</tr>
<tr>
<td>Bhagwan Mahaveer Cancer Hospital &amp; Research Centre</td>
</tr>
<tr>
<td>Bhaktivadanta Hospital &amp; Research Institute</td>
</tr>
<tr>
<td><strong>BANGLADESH</strong></td>
</tr>
<tr>
<td><strong>BELGIUM</strong></td>
</tr>
<tr>
<td><strong>BENIN</strong></td>
</tr>
<tr>
<td>Centre National Hospitalier Universitaire – Hubert K. MAGA</td>
</tr>
<tr>
<td><strong>BHUTAN</strong></td>
</tr>
<tr>
<td>Jigme Dorji Wangchuck National Referral Hospital</td>
</tr>
<tr>
<td><strong>BOLIVIA</strong></td>
</tr>
<tr>
<td>Clinica Los Olivos</td>
</tr>
<tr>
<td>Global Laboratorios</td>
</tr>
<tr>
<td>Hospital de Clinicas Universitario Instituto Boliviano de Oncohematologia</td>
</tr>
<tr>
<td>Instituto Oncologico del Oriente Boliviano</td>
</tr>
<tr>
<td>Private Office Ricardo Villegas</td>
</tr>
<tr>
<td>Private Office Wendy Cabrera</td>
</tr>
</tbody>
</table>
PATIENT PERSPECTIVE

“It is almost 10 years now since I became part of the Max Family. I am amazed by the power of kindhearted words and emotional support. Sounds quite simple, but these two things can take down any barrier in your life. In our life, whenever we come across any difficulty, advice from experienced people plays a key role in overcoming that situation.”

Yogiraj from Pune, India